EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1 ‐Mediated DNA Damage Repair and PI3K / AKT Survival Signaling

Jianghao Yu iD, Siyang Chen, Tingting Hou, Xianwu Weng, Yakun Liu, Junchao Huang, Zeshan Yang, Jinyu Bao, Changshuai Zhou, Wanqing Lv, Qingzhe Wu, Yun Xu iD und 1 weitere

Thoracic Cancer · 2026-09 · 17 (18)

DOI: 10.1111/1759-7714.70393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 22.09.2026. Verfasst von Jianghao Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Center for Oncology Medical, The Fourth Affiliated Hospital of School of Medicine, and International School of …. Hauptthemen laut MEDLINE: Quinolizines, Alkaloids, Lung Neoplasms, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Huadong Medicine Joint Fund of Zhejiang Provincial Natural Science Foundation of China, Science and Technology program of Jinhua Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains a leading cause of cancer‐related mortality worldwide, necessitating the development of novel therapeutic strategies. Matrine, a natural alkaloid derived from Sophora flavescens , has demonstrated broad antitumor properties, yet its underlying mechanisms, particularly concerning DNA damage response, remain incompletely elucidated. This study integrates network pharmacology, bioinformatics, and experimental validation to uncover a novel dual‐targeting mechanism of matrine in lung cancer. Bioinformatics analysis identified CHEK1 as a key potential target. In vitro, matrine selectively inhibited proliferation, migration, invasion, and clonogenic survival of A549 and LLC cells, while reducing the G2/M phase proportion, indicating G2/M checkpoint impairment. Mechanistically, matrine concurrently downregulated CHEK1, p‐PI3K, p‐AKT, BCL‐2, and EMT markers (Vimentin, MMP2, MMP9), and upregulated γH2AX, E‐cadherin, Bax, and Cleaved Caspase‐3. Crucially, siRNA experiments revealed that PI3K knockdown induced apoptosis without affecting CHEK1/γH2AX, whereas CHEK1 silencing promoted apoptosis independently of PI3K/AKT, demonstrating complementary. In vivo, matrine significantly inhibited LLC tumor growth in a xenograft model, suppressed proliferation (Ki67), and modulated the CHEK1‐PI3K/AKT axis, corroborated by IHC and Western blotting. Importantly, matrine exhibited no significant systemic toxicity. Our findings unveil that matrine exerts potent antitumor effects by simultaneously inhibiting CHEK1‐mediated DNA repair and PI3K/AKT survival signaling, presenting a novel dual‐targeting approach for lung cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolizinesAlkaloidsLung NeoplasmsProto-Oncogene Proteins c-aktCheckpoint Kinase 1Phosphatidylinositol 3-KinasesDNA RepairMatrinesHumansAnimalsMiceSignal TransductionDNA DamageXenograft Model Antitumor AssaysCell ProliferationApoptosisDisease Progression

Stichwörter der Autor:innen

CHEK1DNA damage responsePI3K/AKT pathwayapoptosisdual‐mechanism therapylung cancermatrine

Substanzen

QuinolizinesMatrinesAlkaloidsProto-Oncogene Proteins c-aktCheckpoint Kinase 1CHEK1 protein, humanPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, Center for Oncology Medical, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Y…
  • Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zheji…
  • Zhejiang Key Laboratory of Precision Diagnosis and Treatment for Lung Cancer, Yiwu, China.

ORCID-Profile: Jianghao Yu, Yun Xu

Förderung

  • National Natural Science Foundation of China
  • Huadong Medicine Joint Fund of Zhejiang Provincial Natural Science Foundation of China
  • Science and Technology program of Jinhua Science and Technology Bureau

Zitieren

APA

Yu, J., Chen, S., Hou, T., Weng, X., Liu, Y., Huang, J., Yang, Z., Bao, J., Zhou, C., Lv, W., Wu, Q., Xu, Y., & Zhou, J. (2026). Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1 ‐Mediated DNA Damage Repair and PI3K / AKT Survival Signaling. Thoracic Cancer, 17(18). https://doi.org/10.1111/1759-7714.70393

Vancouver

Yu J, Chen S, Hou T, Weng X, Liu Y, Huang J, et al. Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1 ‐Mediated DNA Damage Repair and PI3K / AKT Survival Signaling. Thoracic Cancer. 2026;17(18). doi:10.1111/1759-7714.70393

BibTeX
@article{Yu2026,
  author = {Yu, Jianghao and Chen, Siyang and Hou, Tingting and Weng, Xianwu and Liu, Yakun and Huang, Junchao and Yang, Zeshan and Bao, Jinyu and Zhou, Changshuai and Lv, Wanqing and Wu, Qingzhe and Xu, Yun and Zhou, Jinshan},
  title = {Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1 ‐Mediated DNA Damage Repair and PI3K / AKT Survival Signaling},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {18},
  doi = {10.1111/1759-7714.70393}
}
Kostenlos starten →